Global Intrauterine Devices Market size- Industry Trends & Forecast Report 2027.
The global Intrauterine Devices (IUDs) market is estimated to have reached USD 4.23 billion in 2020 and is further projected to reach USD 5.89 billion by 2027, growing at a CAGR of 5.1% during 2021-2027 (forecast period). The intrauterine devices market is likely to grow in the forecast timeframe due to the increasing rate of unintended pregnancies, along with the supportive government initiatives and private firms for the prevention of unwanted abortions and pregnancies. These devices are gaining popularity as they are effective, safe, long-acting, and eliminate the need for other contraceptives.
Source: BlueWeave Consulting
Global Intrauterine Devices Market Overview:
The intrauterine device is defined as the instrument inserted into the uterus (womb) to prevent conception (pregnancy). The intrauterine device can be a coil, loop, triangle, or T in shape made of plastic or metal. Also, the copper-coated IUD helps in the prevention of the pregnancy by not allowing the sperm to fertilize the egg. It can make it harder for a fertilized egg to implant in the uterus. IUDs have one of the lowest failure rates of any contraceptive method which makes them the best way to prevent pregnancy. IUD is known as a safe and effective contraception method. Currently, a serious complication from IUDs is very rare, although IUD users may be at increased risk of developing the pelvic inflammatory disease.
Intrauterine devices Market Forecast and Trends
Growing awareness regarding the use of IUDs
The IUD is a contraceptive method in the group of long-acting reversible contraception and the growing awareness regarding the benefits of IUDs is acting as the major driving factor for the market, as it is highly effective and safe. Although it is the most widely used reversible method in the world. Furthermore, satisfaction rates rank high among IUD users in the United States (US) compared to other methods, and complication rates are low. The IUD has been emerged as a first-line recommendation for pregnant women with heavy bleeding, pelvic pain, and need for menstrual suppression.
Technological innovations leading to effective contraception
The recent developments in intrauterine technology, smaller frameless copper, and levonorgestrel-releasing devices can help in raising the prevalence of pregnancy. The adolescents and young nulliparous women contribute disproportionately to the epidemic of unintended pregnancies, so, long-acting methods of contraception, particularly IUDs, should be considered as first-line choices for an interval, emergency, and immediate post-oral contraception in this population of women. Also, technology advancements are contributing significantly to the market growth. These devices have less impact on the menstrual pattern after the first few months.
Pelvic Inflammatory Infection
The pelvic inflammatory disease (PID) has been associated with the use of IUDs ever since they were introduced. In most retrospective studies, the incidence of these diseases was suggested to be as high as three- to ninefold in IUD users compared to non-users. Though, later epidemiological prospective studies showed a considerably lower risk comparing different types of contraception. According to the studies, the other non-contraceptive users have the relative risk ranged from 1.8 in patients with copper-containing IUDs to 3.3 in patients using the older insert IUDs like the Dalkon Shield.
Impact of COVID-19 in industry
The global economy and humanity have been pushed into a crisis due to the COVID-19 pandemic. Due to the high infection rate and adverse impact on public health systems, various governments have enforced nationwide lockdowns significantly impacting manufacturing supply chains, trade, and related services. Players are currently considering digital solutions that would enable them to serve the community and provide new opportunities to do business. The production, manufacturing, supply chain, and other operations, have slowed down globally aimed to limit the spread of coronavirus.
The global impact of the coronavirus disease 2019 (COVID-19) is likely only beginning and would significantly affect the Intrauterine Devices market in 2020. The outbreak of COVID-19 has brought with it travel bans and quarantines; massive slowing of the supply chain; uncertainty in the stock market; falling business confidence, and growing panic among the population. Despite the growing uncertainty and panic, technology suppliers must continue to focus on their long-term investments, maintain engagement with partners and prospects, and look to specific markets for stability.
Intrauterine devices Market: By Type
Based on the type, the Intrauterine Devices market is segmented into Hormonal Intrauterine Device, Copper Intrauterine Device. The Hormonal intrauterine device segment followed by Copper Intrauterine Device is likely to dominate the Intrauterine Devices market. The hormonal intrauterine device is a T-shaped plastic frame that's inserted into the uterus, where it releases a type of the hormone progestin. It can provide long-term birth control (contraception). The thickens mucus in the cervix to stop sperm from reaching or fertilizing an egg, also thins the lining of the uterus, and partially suppresses ovulation.
Source: BlueWeave Consulting
Intrauterine Devices Market: Regional Insight
North America region is likely to dominate in the Intrauterine Devices market, followed by Asia pacific, and others. The developing countries like US and Canada have major opportunities for industrial production, retail sales, and fixed-asset investment for the IUDs. Several other economies such as Indonesia, Philippines, and Singapore in the Asia pacific region are also forecast to grow at modest rates. The company's productivity is directly proportional to the productivity of workers. Hence, businesses in these regions are commonly embracing different instruments to help workers increase their productivity.
· In Feb 2020, Agile Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Twirla (levonorgestrel and Ethinyl estradiol) transdermal system. TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
· Recently, Bayer announced that the U.S. Food and Drug Administration (FDA) approved Kyleen (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.
The Intrauterine Devices (IUDs) market is fragmented owing to the presence of number of companies that provides varied IUDs products. However, the companies that hold the majority share of Intrauterine Devices (IUDs) market are Allergan PLC, Bayer AG, CooperSurgical Inc., DKT International, Egemen International, Mona Lisa NV, Pregna International Limited, Prosan International BV, and SMB Corporation of India. OCON Medical, Pregna, SMB Corporation, HLL Lifecare, HRA Pharma, Besins HealthCare and others prominent players.
In the Intrauterine Devices (IUDs) market, prominent market participants compete based on price and product quality. Small and medium-sized market players are expected to show considerable improvements in the foreseeable future, given the moderate level of capital expenditure needed to set up a business. The large-sized companies, however, are likely to aim for global expansion, in a bid to gain a more considerable brand reputation.
Scope of the Report
Historical data – 2016-2019
Base Year – 2020
Forecast – 2021 – 2027
Revenue in USD Billion
U.S, Canada, Germany, UK, France, Italy, Spain, Russia, Brazil, Japan, South Korea, China, UAE, South Africa, UAE, Turkey, India, Rest of APAC, Mexico, Argentina, Rest of Latin America, Saudi Arabia, Rest of MEA, Rest of Europe, GCC
By Type, By End User and By Region
Allergan PLC, Bayer AG, CooperSurgical Inc., DKT International, Egemen International, Mona Lisa NV, Pregna International Limited, Prosan International BV, and SMB Corporation of India. OCON Medical, Pregna, SMB Corporation, HLL Lifecare, HRA Pharma, Besins HealthCare and others.
Scope of the Report
Ø Hormonal Intrauterine Device
Ø Copper Intrauterine Device PET
By End User
Ø Community Healthcare Center
Ø North America
Ø Asia Pacific
Ø Middle East and Africa
Ø Latin America